Number of cases reported from each country of acquisition (464 infections in 459 patients). by Romain Guery (4604179)

Clinical characteristics of patients and healing rates according to treatment administration modality (systemic versus local). by Romain Guery (4604179)

Comparative features of 166 cases of cutaneous, mucocutaneous and mucosal leishmaniasis by main infecting complex species. by Romain Guery (4604179)

Flow chart of entries in the LeishMan database and selected analyses. by Romain Guery (4604179)

Harnessing Infinite Coordination Polymers to Eliminate Harmful Environmental DNA for Water Purification by Zhixuan Yu (14103534)

“…Harmful environmental DNA (eDNA) contamination in water poses significant health risks, yet traditional treatments fall short of achieving efficient removal. …”

Harnessing Infinite Coordination Polymers to Eliminate Harmful Environmental DNA for Water Purification by Zhixuan Yu (14103534)

“…Harmful environmental DNA (eDNA) contamination in water poses significant health risks, yet traditional treatments fall short of achieving efficient removal. …”

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. by Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. by Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. by Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. by Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. by Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. by Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. by Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. by Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... by Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. by Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. by Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... by Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. by Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... by Diana M. Hendrickx (1507435)